DX&Vx Signs Strategic Partnership with Corestem ChemOn to Expand Companion Diagnostic Services

(Left) DXVX CEO Kwon Kyu-chan, CoaStemChemOn President Song Si-hwan. / Photo by DXVX

DXVX announced on the 17th that it has signed a strategic partnership with preclinical CRO company Corestem ChemOn to actively pioneer the companion diagnostics market.

The partnership signing ceremony held at Corestem ChemOn in Yongin was attended by DXVX CEO Kwon Kyu-chan, Research Director Park Sang-jin, New Drug Research Head Lee Kyu-hang, and Corestem ChemOn Preclinical CRO Business Division President Song Si-hwan, Research Director Lee Hyun-geol, and Head Lee Cheol-gyu.

Through this strategic partnership, both companies will promote the establishment and expansion of companion diagnostic services. Corestem ChemOn plans to build a companion diagnostic system that identifies the most suitable anticancer drug among existing therapies by establishing test systems using actual cancer patient tumor tissues. DXVX will support the establishment of Corestem ChemOn’s system for personalized anticancer treatment by leveraging its expertise in genomic analysis technologies and various companion diagnostic analytical methods such as NGS, PCR, FISH, and POCT, as well as its network with major domestic cancer hospitals and related industry-academic institutions. The two companies plan to expand companion diagnostic services targeting targeted anticancer drug development companies in the future.

DXVX’s strategy through this partnership is to actively promote the recently launched companion diagnostic service. Considering that new biomarker discovery typically occurs at the preclinical stage, the ability to reassign preclinical trials for biomarker discovery and validation to Corestem ChemOn is expected to create significant synergy between the two companies.

Companion diagnostics (CDx) are diagnostic techniques used to predict whether a specific drug will be effective for a patient. In 2014, the U.S. FDA recommended the use of companion diagnostics in clinical trials and issued mandatory guidelines for new drug development and companion diagnostics. Integrating companion diagnostics into new drug development can triple the success rate of new drug development and reduce development costs to one-third.

A DXVX official said, “We are pleased to sign a business agreement with Corestem ChemOn, which has outstanding capabilities in the nonclinical field,” and added, “We will cooperate to expand our companion diagnostic services beyond Korea to the global market.”

A Corestem ChemOn official stated, “We expect to accelerate the timeline for new drug development through biomarker development, companion diagnostic services, and efficacy testing of drugs and diagnostics linking nonclinical and clinical stages.”

Meanwhile, in addition to companion diagnostic services, DXVX provides genomic and immunodiagnostic analysis services for stem cell therapeutics and maintaining characteristics of cancer cell lines or confirming genomic instability, as well as immune cell profiling services through nucleotide sequencing analysis of immune cell receptors.

This content was produced with the assistance of AI translation services.